TruScreen posts annual loss, sees blue skies in China

TruScreen posts annual loss, sees blue skies in China
By Paul McBeth June 12 (BusinessDesk) - TruScreen, the NZAX-listed cervical cancer test developer, posted a small loss in its first annual filing as a listed company and has lined up China to underpin growth having achieved regulatory approval and several supply deals in the world's most populous nation. The Auckland-based company reported a loss of $692,000, or 0.5 cents per share, in the 12 months ended March 31 on revenue of $1.57 million, it said in a statement. TruScreen posted a loss of $1.58 million on sales of $19,000 from incorpo...